$1,000 pill now hepatitis C treatment of choice
This undated handout photo provided by Gilead Sciences shows the Hepatitis-C medication Sovaldi. AP
WASHINGTON — A $1,000-per-pill drug that insurers are reluctant to pay for has quickly become the treatment of choice for a liver-wasting viral disease that affects more than 3 million Americans.
According to new research, prescriptions for Sovaldi have eclipsed all other hepatitis C pills combined in less than six months.
The promise of a real cure, with fewer nasty side effects, is enticing thousands of patients to get treated.
It’s by far the strongest launch of any similar drug.
But Sovaldi’s clinical and commercial successes have triggered scrutiny for manufacturer Gilead Sciences Inc., based in California.
Article continues after this advertisementTwo senior U.S. senators are raising questions about documents suggesting that drug developers initially considered a much lower price.
Article continues after this advertisementGilead recently reported its profits more than quadrupled in the second three months of this year.
RELATED STORIES
US urges hepatitis C test for all baby boomers
Hepatitis C no longer a ‘death sentence’
